With the summer holidays drawing to a close, now is the time to be organising your conference calendar to maximise the opportunities these major events in life sciences present. Secure your travel and accommodation while prices are attractive, and availability is high. As an official partner to many of the top events, Optimum is pleased […]
2024 has become a pivotal year in the history of liver diseases with the long-awaited first FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH) – the fatty liver disease that big pharma had targeted for decades. First described in 1980, MASH is the advanced stage of metabolic-dysfunction-associated steatotic liver disease (MASLD) where […]
With summer in full swing, it’s a good time to relax, sit back and listen to Optimum’s amazing podcasts. Available on all the major outlets, you can take it with you anywhere – the office, the train, or even the beach! In Episode #23, we caught up with Dr Ruth McKernan CBE, neuroscientist, businesswoman and […]
Novo Holdings, a leading international life science investor, on Thursday announced a £50m investment in Oxford Nanopore Technologies, the leading UK Listed company behind a new generation of molecular sensing technology based on nanopores. Oxford Nanopore is developing a transformational new generation of sensing technology that specialises in DNA/RNA sequencing. The £50m was invested by […]
Novo Holdings, a leading life science investor, on Tuesday announced that it has led a $105 million financing in Magenta Medical, developer of the Elevate™ System, the world’s smallest heart pump. The financing will be used to advance the company’s US clinical programs in multiple mechanical circulatory support (MCS) indications and to secure the first […]
